E. Bozan, T. Yiğenoğlu, M. Dal, M. Kızıl Çakar, F. Altuntaş
The coexistence of different malignant diseases in the same patient is an entity that can rarely be encountered clinically. This can be observed as the presentation of two distinct types of cancer in the same patient simultaneously or at different times. The genetic structure of the individual, environmental factors and chemotherapeutic agents and radiotherapy used in the treatment of primary disease may play a role in this process. Hodgkin lymphoma is hardly ever observed after non-Hodgkin lymphoma treatment. In this report, we aimed to share two cases that were diagnosed with classical Hodgkin lymphoma in their follow-up after non-Hodgkin lymphoma diagnosis and treatment in our clinic.
{"title":"Hodgkin Lymphoma Identified After Non-Hodgkin Lymphoma: Two Case Reports","authors":"E. Bozan, T. Yiğenoğlu, M. Dal, M. Kızıl Çakar, F. Altuntaş","doi":"10.5505/aot.2022.98470","DOIUrl":"https://doi.org/10.5505/aot.2022.98470","url":null,"abstract":"The coexistence of different malignant diseases in the same patient is an entity that can rarely be encountered clinically. This can be observed as the presentation of two distinct types of cancer in the same patient simultaneously or at different times. The genetic structure of the individual, environmental factors and chemotherapeutic agents and radiotherapy used in the treatment of primary disease may play a role in this process. Hodgkin lymphoma is hardly ever observed after non-Hodgkin lymphoma treatment. In this report, we aimed to share two cases that were diagnosed with classical Hodgkin lymphoma in their follow-up after non-Hodgkin lymphoma diagnosis and treatment in our clinic.","PeriodicalId":435847,"journal":{"name":"Acta Oncologica Turcica","volume":"11 6","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120851267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
C. Mirili, S. Paydaş, A. Yılmaz, A. Oğul, M. Buyuksimsek, A. Yetişir, M. Tohumcuoğlu
{"title":"Prognostic significance of dynamic inflammatory indexes in cases renal cell cancer treated by tyrosine kinase inhibitor (TKI)","authors":"C. Mirili, S. Paydaş, A. Yılmaz, A. Oğul, M. Buyuksimsek, A. Yetişir, M. Tohumcuoğlu","doi":"10.5505/aot.2019.08760","DOIUrl":"https://doi.org/10.5505/aot.2019.08760","url":null,"abstract":"","PeriodicalId":435847,"journal":{"name":"Acta Oncologica Turcica","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125959828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Merve Pamukçuoğlu, A. Güneş, M. Ucar, F. Ceran, M. Falay, G. Özet, S. Dagdas
Objective : Autologous hematopoietic stem cell transplantation is a significant treatment modality for several hematological malignancies and some solid tumors. A sufficient dose of CD34+ stem cell mobilization is a prerequisite for successful autologous hematopoietic stem cell transplantation. Granulocyte colony stimulating factor (G-CSF) is usually used alone or in combination with chemotherapy for mobilization. Two types of G-CSF are used in peripheral blood stem cell mobilization; filgrastim (original or biosimilar) and lenograstim. It was aimed to compare the original filgrastim (Neupogen) with the biosimilar filgrastim (Tevagrastimin) in terms of effectiveness in peripheral blood stem cell mobilization. Materials and Methods: Ninety-five patients who underwent stem cell mobilization between January 2015 and November 2018 in the Bone Marrow Transplant Service of Ankara Numune Training and Research Hospital were analyzed retrospectively. We used Cyclophosphamide (low dose: 2g/m or high dose: 3-4 g/m), as a mobilization regimen, on the first day and G-CSF (Neupogen or Tevagrastim) at a dose of 5 g/kg was started one day after chemotherapy, as a mobilization regimen in all patients. Results: Thirty-nine patients were female and 56 were male. The mean age was 51.24±12.38 years. Sixty-four (67.4%) patients had Multiple Myeloma (MM), 20 (21.1%) patients had non-Hodgkin lymphoma (NHL), and 11 (11.6%) patients had Hodgkin lymphoma (HL). Stem cell mobilization was performed with Neupogen in 50 of ninety-five patients and with Tevagrastim in 45 of them. While there was no statistically significant difference between the demographic characteristics of the patients in terms of age, diagnosis, and whether they received radiotherapy or not (p> 0.05); There was a significant difference in terms of the dose of cyclophosphamide (higher dose cyclophosphamide was used more in the arm receiving Neupogen) and gender (gender distribution in the Neupogen arm was equal, there were more male patients in the Tevagrastim arm) (p<0.05). No statistically significant difference was found between the use of original and biosimilar products in terms of achieving the target of 2x10/kg, which is the minimum CD34 cell dose required for adequate engraftment, and 4x10/kg for double transplantation (p>0.05). However, if the target level of CD34 stem cell was above 6x10/kg, a statistically significant difference was observed in favor of Neupogen compared to the Tevagrastim arm (p=0.021). When the neutrophil engraftment days after autologous stem cell transplantation were compared, it was observed that the neutrophil engraftment was shorter in the Neupogen arm compared to the Tevagrastim arm (approximately 1 day) (p=0.015), while the platelet engraftment was similar in the Neupogen and Tevagrastim arms (p=0.186). Conclusion: While the original and biosimilar filgrastim CD34 cell dose show similar efficacy in reaching the target of 2x10/kg for transplantation and 4x10/kg for double
{"title":"The Comparison of the Biosimilar Filgrastim (Tevagrastim) and the Original Filgrastim (Neupogen) in the Autologous Hematopoetic Stem Cell Mobilization: A Single Center Experience","authors":"Merve Pamukçuoğlu, A. Güneş, M. Ucar, F. Ceran, M. Falay, G. Özet, S. Dagdas","doi":"10.5505/aot.2021.45467","DOIUrl":"https://doi.org/10.5505/aot.2021.45467","url":null,"abstract":"Objective : Autologous hematopoietic stem cell transplantation is a significant treatment modality for several hematological malignancies and some solid tumors. A sufficient dose of CD34+ stem cell mobilization is a prerequisite for successful autologous hematopoietic stem cell transplantation. Granulocyte colony stimulating factor (G-CSF) is usually used alone or in combination with chemotherapy for mobilization. Two types of G-CSF are used in peripheral blood stem cell mobilization; filgrastim (original or biosimilar) and lenograstim. It was aimed to compare the original filgrastim (Neupogen) with the biosimilar filgrastim (Tevagrastimin) in terms of effectiveness in peripheral blood stem cell mobilization. Materials and Methods: Ninety-five patients who underwent stem cell mobilization between January 2015 and November 2018 in the Bone Marrow Transplant Service of Ankara Numune Training and Research Hospital were analyzed retrospectively. We used Cyclophosphamide (low dose: 2g/m or high dose: 3-4 g/m), as a mobilization regimen, on the first day and G-CSF (Neupogen or Tevagrastim) at a dose of 5 g/kg was started one day after chemotherapy, as a mobilization regimen in all patients. Results: Thirty-nine patients were female and 56 were male. The mean age was 51.24±12.38 years. Sixty-four (67.4%) patients had Multiple Myeloma (MM), 20 (21.1%) patients had non-Hodgkin lymphoma (NHL), and 11 (11.6%) patients had Hodgkin lymphoma (HL). Stem cell mobilization was performed with Neupogen in 50 of ninety-five patients and with Tevagrastim in 45 of them. While there was no statistically significant difference between the demographic characteristics of the patients in terms of age, diagnosis, and whether they received radiotherapy or not (p> 0.05); There was a significant difference in terms of the dose of cyclophosphamide (higher dose cyclophosphamide was used more in the arm receiving Neupogen) and gender (gender distribution in the Neupogen arm was equal, there were more male patients in the Tevagrastim arm) (p<0.05). No statistically significant difference was found between the use of original and biosimilar products in terms of achieving the target of 2x10/kg, which is the minimum CD34 cell dose required for adequate engraftment, and 4x10/kg for double transplantation (p>0.05). However, if the target level of CD34 stem cell was above 6x10/kg, a statistically significant difference was observed in favor of Neupogen compared to the Tevagrastim arm (p=0.021). When the neutrophil engraftment days after autologous stem cell transplantation were compared, it was observed that the neutrophil engraftment was shorter in the Neupogen arm compared to the Tevagrastim arm (approximately 1 day) (p=0.015), while the platelet engraftment was similar in the Neupogen and Tevagrastim arms (p=0.186). Conclusion: While the original and biosimilar filgrastim CD34 cell dose show similar efficacy in reaching the target of 2x10/kg for transplantation and 4x10/kg for double","PeriodicalId":435847,"journal":{"name":"Acta Oncologica Turcica","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127427502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Arslan, İ. Aral, G. Inan, H. Karabuğa, S. Açıkgöz, İlhami Ünal, F. Altıntaş, S. Tekin, H. Ozturk, Y. Tezcan
INTRODUCTION: Lung cancer (LC) is the most common malignities and still remain the leading cause of cancer deaths. The aims of this study are to assess the effect of cigarette smoking on the localization and effect of the location of tumors on the prognosis and acute adverse effects. METHODS: 72 patients that given curative thoracic radiotherapy between 24.11.11-14.9.16 in Ankara Atatürk Educational Research Hospital with diagnosed lung cancer were evaluated, retrospectively. Patients diagnosed with LC and underwent curative radiotherapy (RT) were included. Primer endpoints are the acute adverse effect and overall survey (OS). RESULTS: Sixty-five patients (%90,3), were male and seven (%9,7) were female. Tumor localization was 62,5% on the right side and 37.5% on the left side. 62.5% of the patients had concurrent chemotherapy. Median follow-up is 2 years. While the right lung cancer was significantly higher in patients who smoked in NSCLC than in the left lung (p0,05), this ratio was not significant in SCLC (p0,5). There is also an increase in left lung localization with increasing age in all group (p0,2). Acute side effects in NSCLC are more severe in the right lung (p0,043). In the NSCLC group, ARP developed in all 5 patients who smoked more than 50 pct and this ratio is significantly higher than in patients who smoke less than 50 pct year (p0,044). ARP in NSCLC patients is significantly more common in the right lung (p0,05) but there was no significant difference in SCLC (p 0,1). There are no statistically difference in OS between right and left lung cancer. DISCUSSION AND CONCLUSION: LC is often seen in the right lung. Similarly, the acute pulmonary side effects are also more frequently observed on the right side in NSLC. There are no statistically difference in OS between right and left lung cancer.
{"title":"Right predilection of lung cancer, does it affect oncologic outcome?","authors":"S. Arslan, İ. Aral, G. Inan, H. Karabuğa, S. Açıkgöz, İlhami Ünal, F. Altıntaş, S. Tekin, H. Ozturk, Y. Tezcan","doi":"10.5505/aot.2019.01488","DOIUrl":"https://doi.org/10.5505/aot.2019.01488","url":null,"abstract":"INTRODUCTION: Lung cancer (LC) is the most common malignities and still remain the leading cause of cancer deaths. The aims of this study are to assess the effect of cigarette smoking on the localization and effect of the location of tumors on the prognosis and acute adverse effects. METHODS: 72 patients that given curative thoracic radiotherapy between 24.11.11-14.9.16 in Ankara Atatürk Educational Research Hospital with diagnosed lung cancer were evaluated, retrospectively. Patients diagnosed with LC and underwent curative radiotherapy (RT) were included. Primer endpoints are the acute adverse effect and overall survey (OS). RESULTS: Sixty-five patients (%90,3), were male and seven (%9,7) were female. Tumor localization was 62,5% on the right side and 37.5% on the left side. 62.5% of the patients had concurrent chemotherapy. Median follow-up is 2 years. While the right lung cancer was significantly higher in patients who smoked in NSCLC than in the left lung (p0,05), this ratio was not significant in SCLC (p0,5). There is also an increase in left lung localization with increasing age in all group (p0,2). Acute side effects in NSCLC are more severe in the right lung (p0,043). In the NSCLC group, ARP developed in all 5 patients who smoked more than 50 pct and this ratio is significantly higher than in patients who smoke less than 50 pct year (p0,044). ARP in NSCLC patients is significantly more common in the right lung (p0,05) but there was no significant difference in SCLC (p 0,1). There are no statistically difference in OS between right and left lung cancer. DISCUSSION AND CONCLUSION: LC is often seen in the right lung. Similarly, the acute pulmonary side effects are also more frequently observed on the right side in NSLC. There are no statistically difference in OS between right and left lung cancer.","PeriodicalId":435847,"journal":{"name":"Acta Oncologica Turcica","volume":"60 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130363442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Uysal, M. Erkurt, I. Kuku, E. Kaya, İ. Berber, A. Sarici, S. Biçim, Ahmet Kaya, Emine Hidayet
{"title":"How are the Results of Allogeneic Stem Cell Transplantation in Elderly Patients? A Single-center Experience","authors":"A. Uysal, M. Erkurt, I. Kuku, E. Kaya, İ. Berber, A. Sarici, S. Biçim, Ahmet Kaya, Emine Hidayet","doi":"10.5505/aot.2023.70487","DOIUrl":"https://doi.org/10.5505/aot.2023.70487","url":null,"abstract":"","PeriodicalId":435847,"journal":{"name":"Acta Oncologica Turcica","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127815114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ö. Açıkgöz, Sabin Göktaş Aydın, A. Bilici, Yasin Kutlu, Harun Muğlu, E. Karci, J. Hamdard, E. Mammadov, Ö. Ölmez, Özcan Yıldız
{"title":"The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients","authors":"Ö. Açıkgöz, Sabin Göktaş Aydın, A. Bilici, Yasin Kutlu, Harun Muğlu, E. Karci, J. Hamdard, E. Mammadov, Ö. Ölmez, Özcan Yıldız","doi":"10.5505/aot.2023.00187","DOIUrl":"https://doi.org/10.5505/aot.2023.00187","url":null,"abstract":"","PeriodicalId":435847,"journal":{"name":"Acta Oncologica Turcica","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125328647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tuncay Tunccan, Elif Akyol Sen, S. Toros, A. Ant, A. Duran
INTRODUCTION: Evaluation of taste and smell senses alteration in total laryngectomy MATERIAL and METHODS: The materials which were used for evaluation of taste and smell senses were easily provided and the tests were non-invasive. The smell sense was evaluated by using CCCRC smell identification test and n-butanol thresold test where taste sense was evaluated by using 3 different concentrations (low-medium-high) of four main taste (sweet, bitter, sour and salty) solutions. Results of taste and smell evaluation tests were statistically analized. RESULTS: Anosmia and severe hyposmia were evaluated in smell sense tests of total laryngectomy received patients. This finding shows the disfunction of smell sense in total laryngectomy. Different results of taste sense tests were found according to the kind and concentration of solutions; patients sensed sour solutions better than sweet, bitter and salty solutions. DISCUSSION AND CONCLUSION: Total laryngectomy can causes decrease in olfactory functions and taste
{"title":"How does total laryngectomy affect taste and smell senses","authors":"Tuncay Tunccan, Elif Akyol Sen, S. Toros, A. Ant, A. Duran","doi":"10.5505/AOT.2019.04880","DOIUrl":"https://doi.org/10.5505/AOT.2019.04880","url":null,"abstract":"INTRODUCTION: Evaluation of taste and smell senses alteration in total laryngectomy MATERIAL and METHODS: The materials which were used for evaluation of taste and smell senses were easily provided and the tests were non-invasive. The smell sense was evaluated by using CCCRC smell identification test and n-butanol thresold test where taste sense was evaluated by using 3 different concentrations (low-medium-high) of four main taste (sweet, bitter, sour and salty) solutions. Results of taste and smell evaluation tests were statistically analized. RESULTS: Anosmia and severe hyposmia were evaluated in smell sense tests of total laryngectomy received patients. This finding shows the disfunction of smell sense in total laryngectomy. Different results of taste sense tests were found according to the kind and concentration of solutions; patients sensed sour solutions better than sweet, bitter and salty solutions. DISCUSSION AND CONCLUSION: Total laryngectomy can causes decrease in olfactory functions and taste","PeriodicalId":435847,"journal":{"name":"Acta Oncologica Turcica","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126489976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Murat Kacmaz, S. Başcı, S. Yaman, Burcu Aslan Candır, S. Seçilmiş, Gül Ilhan, T. Yiğenoğlu, M. Kızıl Çakar, M. Dal, F. Altuntaş
{"title":"Uric Acid and Multiple Myeloma, Unexplored Association","authors":"Murat Kacmaz, S. Başcı, S. Yaman, Burcu Aslan Candır, S. Seçilmiş, Gül Ilhan, T. Yiğenoğlu, M. Kızıl Çakar, M. Dal, F. Altuntaş","doi":"10.5505/aot.2023.25901","DOIUrl":"https://doi.org/10.5505/aot.2023.25901","url":null,"abstract":"","PeriodicalId":435847,"journal":{"name":"Acta Oncologica Turcica","volume":"203 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122762515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：